NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first transcatheter tricuspid valved stent is successfully implanted


Dec 30, 2016   •  Business Wire

LAKE FOREST, Calif., Dec. 30, 2016 — NaviGate Cardiac Structures Inc. ("NCSI") announced today that a novel valved stent that can capture the enlarged annulus in patients suffering from functional tricuspid regurgitation (FTR) was implanted in a patient presenting with massive incompetence of the tricuspid valve. The patient, a 64-year-old female with an extensive history of severe tricuspid…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc., presents data of studies on the Gate™ valved stent for correction of Functional Tricuspid Regurgitation at Paris PCR2016.


Jun 23, 2016   •  Announcement

Jose L Navia, M.D., from Cleveland Clinic presented the summary of animal studies of the Gate™valved stent for catheter-guided orthotopic implantation procedure for the correction of Functional Tricuspid Regurgitation (FTR).  Functional tricuspid regurgitation occurs yearly in close to 2 million patients in the USA, as reported by Stuge & Liddicoat previously.  These patients are for a large part categorized as inoperable by the STS (Society of Thoracic Surgery) guidelines, that is, at…

Continue Reading

First NAVI™ patient at 8 months shows excellent mitral valve function and has returned to work


Jun 23, 2016   •  Announcement

NaviGate Cardiac Structures, Inc. has received approval from Krakow, Poland, Ethics Committee  to implant the Navi™ Valved Stent for correction of severe Functional Mitral Regurgitation (FMR). NCSI has received approval from the regional Ethics Committee to implant the Navi™valved stent for the correction of severe mitral regurgitation (MR) in patients considered inoperable by standard cardiac surgery that requires open chest, open and arrested heart and cardiopulmonary bypass because of…

Continue Reading

NaviGate Cardiac Structures Inc. (“NCSI”) reports first patient treated for mitral regurgitation (“MR”)


Nov 23, 2015   •  Business Wire

LAKE FOREST, Calif. – NaviGate Cardiac Structures Inc. (NCSI) announced today that a First-In-Human implant of it's catheter-guided, mitral-valved stent into a beating heart was performed successfully in a 53-year-old male patient presenting with severe 4+* MR. The interventional team was led by Dr. Cristián Baeza Prieto at San Borja Arriarán Hospital in Santiago, Chile, on October 26, 2015.…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108